Valuation: SANA AB

Market Cap 1.3B 130M 116M 108M 98.44M 185M 12.51B 188M 505M 6.38B 487M 477M 20.68B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.3B 130M 116M 108M 98.44M 185M 12.51B 188M 505M 6.38B 487M 477M 20.68B EV / Sales 2026 *
12.7x
EV / Sales 2027 * 6.24x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day-3.18%
1 week-4.55%
Current month-3.18%
1 month-17.40%
3 months-27.92%
6 months-39.89%
Current year-55.42%
1 week 9.36
Extreme 9.355
10.19
1 month 9.36
Extreme 9.355
12.07
Current year 9.36
Extreme 9.355
28.3
1 year 9.36
Extreme 9.355
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 28/02/2025
Chief Executive Officer 66 29/04/2022
Chief Tech/Sci/R&D Officer 68 31/12/2013
Director TitleAgeSince
Chairman 71 29/04/2022
Director/Board Member 68 31/12/2014
Director/Board Member 46 18/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Buy

Chairman

50,000 0.0362%
01/09/26 Buy

Founder

9,000 0.0065%
28/08/26 Buy

Chief Financial Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-3.18%-4.55%-19.09%+49.05% 135M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -0.36%+1.63%+47.98%+143.75% 39.69B
Weighted average by Cap. +0.17%+1.83%+60.04%+145.75%

Financials

2026 *2027 *
Net sales 103M 10.28M 9.13M 8.53M 7.78M 14.6M 988M 14.82M 39.93M 504M 38.53M 37.69M 1.63B 209M 20.85M 18.53M 17.31M 15.79M 29.63M 2.01B 30.07M 81.02M 1.02B 78.18M 76.48M 3.32B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
01/10/26 SEK 9.450 -3.18% 228,815
30/09/26 SEK 9.760 +1.83% 166,671
29/09/26 SEK 9.585 +1.37% 397,660
28/09/26 SEK 9.455 -2.63% 381,393
25/09/26 SEK 9.710 -1.12% 379,612

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock